AstraZeneca has made several news headlines for its environmental sustainability pledges, including deals for renewable natural gas and a commitment to plant hundreds of millions of trees.

In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions.

To learn more about the topics in this episode: 


Fellowship of the green: AstraZeneca, Samsung, GSK and more unite to slash greenhouse gas emissions


AstraZeneca sows $400M investment in push to plant 200M trees by 2030


From farm to pharma: AstraZeneca inks renewable natural gas pact to shrink environmental footprint

AstraZeneca has made several news headlines for its environmental sustainability pledges, including deals for renewable natural gas and a commitment to plant hundreds of millions of trees.
In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions.
To learn more about the topics in this episode: 
<ul>
<li>
<a href="https://www.fiercepharma.com/pharma/fellowship-green-astrazeneca-samsung-gsk-and-4-other-eco-minded-pharma-majors-unite-slash">Fellowship of the green: AstraZeneca, Samsung, GSK and more unite to slash greenhouse gas emissions</a>
</li>
<li>
<a href="https://www.fiercepharma.com/pharma/astrazeneca-sows-400m-investment-push-plant-200m-trees-2030">AstraZeneca sows $400M investment in push to plant 200M trees by 2030</a>
</li>
<li>
<a href="https://www.fiercepharma.com/manufacturing/farm-pharma-astrazeneca-inks-renewable-natural-gas-pact-shrink-environmental">From farm to pharma: AstraZeneca inks renewable natural gas pact to shrink environmental footprint</a>
</li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Exploring AstraZeneca's environmental pledges

After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration’s import tariff policy for drugs. While many of the industry’s biggest firms have navigated the trade threat through investment pledges and drug pricing deals, the current landscape remains murkier for small- and mid-sized drugmakers.

In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner sits down with Chris Young, a principal in KPMG’s trade and customs practice, to discuss the pharma tariff landscape following President Donald Trump’s announcement in early April of a potential 100% tariff on imported drugs. Young explains how the policy could affect smaller drugmakers that haven’t inked high-profile pricing deals with the government and shares best practices for navigating the rapidly evolving U.S. trade environment.

To learn more about the topics in this episode: 
An update on the pharma industry’s reshoring effort
Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg
Trump's tariff threats, measured by manufacturing
UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments

After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration&rsquo;s import tariff policy for drugs. While many of the industry&rsquo;s biggest firms have navigated the trade threat through investment pledges and drug pricing deals, the current landscape remains murkier for small- and mid-sized drugmakers.
In this episode of &ldquo;The Top Line,&rdquo; Fierce Pharma&rsquo;s Fraiser Kansteiner sits down with Chris Young, a principal in KPMG&rsquo;s trade and customs practice, to discuss the pharma tariff landscape following President Donald Trump&rsquo;s announcement in early April of a potential 100% tariff on imported drugs. Young explains how the policy could affect smaller drugmakers that haven&rsquo;t inked high-profile pricing deals with the government and shares best practices for navigating the rapidly evolving U.S. trade environment.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/update-pharma-industrys-reshoring-effort">An update on the pharma industry&rsquo;s reshoring effort</a></li>
<li><a href="https://www.fiercepharma.com/pharma/trump-set-impose-100-tariff-drugs-companies-have-not-struck-mfn-deals">Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/trumps-tariff-threats-measured-manufacturing">Trump's tariff threats, measured by manufacturing</a></li>
<li><a href="https://www.fiercepharma.com/pharma/uk-government-signs-us-uk-pharma-deal-ensuring-0-drug-tariffs-britain-looks-re-attract">UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments</a></li>
</ul>

Revisiting Pharma’s tariff reality

In this sponsored episode of The Top Line, host Kelly Hogan speaks with Dr. Bettine Boltres, director of scientific affairs, integrated systems at West Pharmaceutical Services, about the development of the West Synchrony prefillable syringe system. As drug pipelines grow and regulatory expectations increase, pharma and biotech companies face mounting pressure to reduce complexity while accelerating development timelines. 

Dr. Boltres explains how West Synchrony addresses these challenges by offering a fully integrated system rather than a collection of individual components. By providing complete design verification data, system level specifications and a single global regulatory package, West enables developers to eliminate redundant testing, streamline submissions and move more quickly into clinical fill. 

The discussion highlights the benefits of single supplier accountability, improved supply security and reduced risk across development and commercialization. Designed for biologics and modern vaccines, West Synchrony sets a new standard in prefillable syringe systems.

In this sponsored episode of The Top Line, host Kelly Hogan speaks with Dr. Bettine Boltres, director of scientific affairs, integrated systems at West Pharmaceutical Services, about the development of the West Synchrony&nbsp;prefillable&nbsp;syringe system. As drug pipelines grow and regulatory expectations increase, pharma and biotech companies face mounting pressure to reduce complexity while accelerating development timelines.&nbsp;
Dr. Boltres explains how West Synchrony addresses these challenges by offering a fully integrated system rather than a collection of individual components. By providing complete design verification data, system level specifications and a single global regulatory package, West enables developers to&nbsp;eliminate&nbsp;redundant testing, streamline&nbsp;submissions&nbsp;and move more quickly into clinical fill.&nbsp;
The discussion highlights the benefits of single supplier accountability, improved supply security and reduced risk across development and commercialization. Designed for biologics and modern vaccines, West Synchrony sets a new standard in prefillable syringe systems.

Setting a new standard in prefillable syringe systems (Sponsored)

Theranostics is transforming cancer care, but scaling these treatments requires overcoming operational and workforce challenges. In this episode of The Top Line, Curium’s Mike Patterson discusses how access, safety and trust are shaping the next phase of growth for targeted radiopharmaceutical therapies.

 

Patterson explains why strong coordination across ordering, manufacturing and distribution is essential to delivering therapies on time. He also explores how building trust with physicians, care teams and patients requires education, consistent communication and reliable support at every stage of the treatment process.

 

As theranostics expands into community settings, new challenges are emerging. Workforce shortages, training needs and the importance of standardized practices are key considerations for scaling safely. Patterson shares how industry collaboration can help address these gaps while maintaining high standards of care.

 

He also outlines a future defined by greater access, reduced travel burdens and a more seamless patient experience. Listen to the full episode to learn how Curium is working to make theranostics more accessible across the United States.

Theranostics is transforming cancer care, but scaling these treatments requires overcoming operational and workforce challenges. In this episode of The Top Line, Curium&rsquo;s Mike Patterson discusses how access, safety and trust are shaping the next phase of growth for targeted radiopharmaceutical therapies.
&nbsp;
Patterson explains why strong coordination across ordering, manufacturing and distribution is essential to delivering therapies on time. He also explores how building trust with physicians, care teams and patients requires education, consistent communication and reliable support at every stage of the treatment process.
&nbsp;
As theranostics expands into community settings, new challenges are emerging. Workforce shortages, training needs and the importance of standardized practices are key considerations for scaling safely. Patterson shares how industry collaboration can help address these gaps while maintaining high standards of care.
&nbsp;
He also outlines a future defined by greater access, reduced travel burdens and a more seamless patient experience. Listen to the full episode to learn how Curium is working to make theranostics more accessible across the United States.

Exploring AstraZeneca's environmental pledges

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips